Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting, 53787 [2015-22068]

Download as PDF Federal Register / Vol. 80, No. 173 / Tuesday, September 8, 2015 / Notices and implement an efficient personal property program to facilitate quality movements for our military members and civilian employees, all business rules are developed in concert with the Military Services and Surface Deployment and Distribution Command. Any subsequent modification(s) to the business rules will be published in the Federal Register and incorporated into the Defense Transportation Regulation (DTR) Part IV (DTR 4500.9R). The Government shall comply with the Small Business Act, 15 U.S.C. 644(a). These program requirements do not impose a legal requirement, obligation, sanction or penalty on the public sector, and will not have an economic impact of $100 million or more. Additional Information A complete version of the DTR is available via the Internet on the USTRANSCOM homepage at https:// www.transcom.mil/dtr/part-iv/. Dated: September 2, 2015. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2015–22524 Filed 9–4–15; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF DEFENSE Office of the Secretary Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting Assistant Secretary of Defense (Health Affairs), DoD. ACTION: Notice of meeting. AGENCY: The Department of Defense is publishing this notice to announce a Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (hereafter referred to as the Panel). DATES: Wednesday, September 30, 2015, from 9 a.m. to 1 p.m. ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., Washington, DC 20004. FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, DFO, Uniform Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042–5101. Telephone: (703) 681–2890. Fax: (703) 681–1940. Email Address: dha.ncr.health-it.mbx.baprequests@ mail.mil. asabaliauskas on DSK5VPTVN1PROD with NOTICES SUMMARY: This meeting is being held under the SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:18 Sep 04, 2015 Jkt 235001 provisions of the Federal Advisory Committee Act of 1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended). Purpose of Meeting: The Panel will review and comment on recommendations made to the Director of Defense Health Agency, by the Pharmacy and Therapeutics Committee, regarding the Uniform Formulary. Meeting Agenda 1. Sign-In 2. Welcome and Opening Remarks 3. Public Citizen Comments 4. Scheduled Therapeutic Class Reviews (Comments will follow each agenda item) a. Diabetes Non-Insulin (GLP–1 Receptor Agonists) b. Diabetes Non-Insulin (SGLT–2 Inhibitors) c. Narcotics Analgesics—Long Acting d. Oral Oncological Agents—CML Drugs 5. Designated Newly Approved Drugs in Already-Reviewed Classes 6. Pertinent Utilization Management Issues 7. Panel Discussions and Vote Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 41 Code of Federal Regulations (CFR) 102–3.140 through 102–3.165, and the availability of space, this meeting is open to the public. Seating is limited and will be provided only to the first 220 people signing-in. All persons must sign-in legibly. Administrative Work Meeting: Prior to the public meeting, the Panel will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to discuss administrative matters of the Panel. The Administrative Work Meeting will be held at the Naval Heritage Center, 701 Pennsylvania Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102– 3.160, the Administrative Work Meeting will be closed to the public. Written Statements: Pursuant to 41 CFR 102–3.140, the public or interested organizations may submit written statements to the membership of the Panel at any time or in response to the stated agenda of a planned meeting. Written statements should be submitted to the Panel’s Designated Federal Officer (DFO). The DFO’s contact information can be obtained from the General Services Administration’s Federal Advisory Committee Act Database at https://facadatabase.gov/.Written statements that do not pertain to the scheduled meeting of the Panel may be submitted at any time. However, if individual comments pertain to a PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 53787 specific topic being discussed at a planned meeting, then these statements must be submitted no later than 5 business days prior to the meeting in question. The DFO will review all submitted written statements and provide copies to all the committee members. Public Comments: In addition to written statements, the Panel will set aside 1 hour for individuals or interested groups to address the Panel. To ensure consideration of their comments, individuals and interested groups should submit written statements as outlined in this notice; but if they still want to address the Panel, then they will be afforded the opportunity to register to address the Panel. The Panel’s DFO will have a ‘‘Sign-Up Roster’’ available at the Panel meeting for registration on a first-come, first-serve basis. Those wishing to address the Panel will be given no more than 5 minutes to present their comments, and at the end of the 1 hour time period, no further public comments will be accepted. Anyone who signs-up to address the Panel, but is unable to do so due to the time limitation, may submit their comments in writing; however, they must understand that their written comments may not be reviewed prior to the Panel’s deliberation. To ensure timeliness of comments for the official record, the Panel encourages that individuals and interested groups consider submitting written statements instead of addressing the Panel. Dated: September 1, 2015. Aaron Siegel, Alternate OSD Federal Register Liaison Officer, Department of Defense. [FR Doc. 2015–22068 Filed 9–4–15; 8:45 am] BILLING CODE 5001–06–P DEPARTMENT OF EDUCATION President’s Board of Advisors on Historically Black Colleges and Universities President’s Board of Advisors on Historically Black Colleges and Universities, Office of Undersecretary, U.S. Department of Education. ACTION: Announcement of an open meeting. AGENCY: This notice sets forth the agenda for the September 23, 2015, meeting of the President’s Board of Advisors on Historically Black Colleges and Universities (PBA) and provides information to members of the public on submitting written comments and on the process as to how to request time to SUMMARY: E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 80, Number 173 (Tuesday, September 8, 2015)]
[Notices]
[Page 53787]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-22068]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Assistant Secretary of Defense (Health Affairs), DoD.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense is publishing this notice to 
announce a Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: Wednesday, September 30, 2015, from 9 a.m. to 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 
5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. Fax: 
(703) 681-1940. Email Address: dha.ncr.health-it.mbx.baprequests@mail.mil.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act of 1972 (Title 5, 
United States Code (U.S.C.), Appendix, as amended) and the Government 
in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended).
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of Defense Health Agency, by the 
Pharmacy and Therapeutics Committee, regarding the Uniform Formulary.

Meeting Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Diabetes Non-Insulin (GLP-1 Receptor Agonists)
    b. Diabetes Non-Insulin (SGLT-2 Inhibitors)
    c. Narcotics Analgesics--Long Acting
    d. Oral Oncological Agents--CML Drugs
    5. Designated Newly Approved Drugs in Already-Reviewed Classes
    6. Pertinent Utilization Management Issues
    7. Panel Discussions and Vote
    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 Code of Federal Regulations (CFR) 102-3.140 through 102-3.165, and 
the availability of space, this meeting is open to the public. Seating 
is limited and will be provided only to the first 220 people signing-
in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel at any time or in response to the stated agenda 
of a planned meeting. Written statements should be submitted to the 
Panel's Designated Federal Officer (DFO). The DFO's contact information 
can be obtained from the General Services Administration's Federal 
Advisory Committee Act Database at https://facadatabase.gov/.Written 
statements that do not pertain to the scheduled meeting of the Panel 
may be submitted at any time. However, if individual comments pertain 
to a specific topic being discussed at a planned meeting, then these 
statements must be submitted no later than 5 business days prior to the 
meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.
    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: September 1, 2015.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2015-22068 Filed 9-4-15; 8:45 am]
BILLING CODE 5001-06-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.